November 5, 2009

HELIX BIOPHARMA CORP COMPLETES ENROLLMENT IN ITS PHASE II TRIAL OF TOPICAL INTERFERON ALPHA-2B IN PATIENTS WITH ANO-GENITAL WARTS (PDF)

(AURORA, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: HXBPF) announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.